Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Frontiers in Genetics National Center of Competence in Research, Ecole Polytechnique Fédérale de Lausanne, Station 19, 1015 Lausanne, Switzerland.
Biochimie. 2012 Mar;94(3):854-63. doi: 10.1016/j.biochi.2011.12.004. Epub 2011 Dec 9.
Telomerase is responsible for the immortal phenotype of cancer cells and telomerase inhibition may specifically target cancer cell proliferation. Ligands able to selectively bind to G-quadruplex telomeric DNA have been considered as telomerase inhibitors but their mechanisms of action have often been deduced from a non-quantitative telomerase activity assay (TRAP assay) that involves a PCR step and that does not provide insight on the mechanism of inhibition. Furthermore, quadruplex ligands have also been shown to exert their effects by affecting association of telomere binding proteins with telomeres. Here, we use quantitative direct telomerase activity assays to evaluate the strength and mechanism of action of hydrosoluble perylene diimides (HPDIs). HPDIs contain a perylene moiety and different numbers of positively charged side chains. Side chain features vary with regard to number and distances of the charges. IC(50) values of HPDIs were in the low micromolar (0.5-5 μM) range depending on the number and features of the side chains. HPDIs having four side chains emerged as the best compounds of this series. Analysis of primer elongation products demonstrated that at low HPDI concentrations, telomerase inhibition involved formation of telomeric G-quadruplex structures, which inhibited further elongation by telomerase. At high HPDI concentrations, telomerase inhibition occurred independently of G-quadruplex formation of the substrate. The mechanism of action of HPDIs and their specific binding to G-quadruplex DNA was supported by PAGE analysis, CD spectroscopy and ESI-MS. Finally, competition Telospot experiments with duplex DNA indicated specific binding of HPDIs to the single-stranded telomeric substrates over double stranded DNA, a result supported by competitive ESI-MS. Altogether, our results indicate that HPDIs act by stabilizing G-quadruplex structures in single-stranded telomeric DNA, which in turn prevents repeat addition processivity of telomerase.
端粒酶负责癌细胞的不朽表型,端粒酶抑制可能特异性地靶向癌细胞增殖。能够选择性地与 G-四链体端粒 DNA 结合的配体已被认为是端粒酶抑制剂,但它们的作用机制通常是从非定量端粒酶活性测定 (TRAP 测定) 中推断出来的,该测定涉及 PCR 步骤,并且不能提供关于抑制机制的见解。此外,四链体配体也被证明通过影响端粒结合蛋白与端粒的结合来发挥作用。在这里,我们使用定量直接端粒酶活性测定来评估水溶性苝二酰亚胺 (HPDI) 的强度和作用机制。HPDI 包含苝部分和不同数量的正电荷侧链。侧链特征在电荷的数量和距离上有所不同。根据侧链的数量和特征,HPDI 的 IC50 值在低微摩尔 (0.5-5 μM) 范围内。具有四个侧链的 HPDI 是该系列中最好的化合物。引物延伸产物分析表明,在低 HPDI 浓度下,端粒酶抑制涉及形成端粒 G-四链体结构,这抑制了端粒酶的进一步延伸。在高 HPDI 浓度下,端粒酶抑制的发生不依赖于底物 G-四链体的形成。HPDI 的作用机制及其与 G-四链体 DNA 的特异性结合得到了 PAGE 分析、CD 光谱和 ESI-MS 的支持。最后,与双链 DNA 的 Telospot 竞争实验表明,HPDI 特异性结合于单链端粒底物而不是双链 DNA,这一结果得到了竞争性 ESI-MS 的支持。总之,我们的结果表明,HPDI 通过稳定单链端粒 DNA 中的 G-四链体结构来发挥作用,这反过来又阻止了端粒酶的重复添加过程性。